

136. The regulation of hormone-dependent adenylate cyclase in native membranes and systems reconstituted from purified components.  
A. Levitzki.  
In: "Biomembrane and Receptor Mechanisms" (D. Chapman and E. Bertoli, eds.) Liviana Press, Padua, Italy, pp. 225-235 (1986).
137. Regulation of adenylate cyclase by hormones and G-proteins  
A. Levitzki.  
FEBS Lett. 211, 113-118 (1987).
138. Characterization of the  $\beta_2$ -adrenoceptor-dependent adenylate cyclase of A431 epidermoid carcinoma cells.  
O. Kashles and A. Levitzki.  
Biochem. Pharmacol., 36, 1531-1538 (1987).
139. An accurate method for the determination of receptor-ligand in enzyme-inhibitor constants from displacement curves.  
A. Horovitz and A. Levitzki.  
Proc. Nat. Acad. Sci. USA, 84, 6654-6658 (1987).
140. The activation of adenylate cyclase by guanyl nucleotides in *Saccharomyces cerevisiae* is controlled by the CDC25 start gene product.  
J. Daniel, J.M. Becker, E. Enari and A. Levitzki.  
Mol. Cell. Biol., 7 (10), 3857-3861 (1987).
141. Signal transduction in hormone dependent adenylate cyclase.  
A. Levitzki.  
Cell Biophysics, 12, 133-143 (1987).
142. Coupling of  $\beta$ -adrenoceptors to adenylate cyclase and the role of the GTP binding protein in signal transduction.  
A. Levitzki.  
In: "Perspectives on Receptor Classification" (J.W. Black, D.M. Jenkinson and Y.P. Gerskowitch, eds.) Alan Liss, pp. 87-94 (1987).
143. Regulation of hormone sensitive adenylate cyclase  
A. Levitzki  
Trends in Pharmacol. Sci. (TIPS), 8, 299-303 (1987).
144. Signal transduction in  $\beta$ -adrenoceptor-dependent adenylate cyclase.  
A. Levitzki.  
In: "Enzyme Dynamics and Regulation", eds. P. Boon Chock, C. L. Tsou, C. Y. Huang and J. H. Wang, Springer-Verlag, pp. 113-120 (1987).
145. Gi affects the agonist binding properties of  $\beta$ -adrenoceptors in the presence of Gs.  
I. Marbach, J. Shiloach and A. Levitzki.  
Eur. J. Biochem., 172, 239-246 (1988).
146. Guanine nucleotide regulation of adenylate cyclase in permeabilized cells of *Saccharomyces cerevisiae*.  
J.M. Becker, B. Enari and A. Levitzki.  
Biochim. Biophys. Acta, 968, 408-417 (1988).
147. From epinephrine to cAMP.  
A. Levitzki.  
Science, 241, 800-806 (1988).
148. Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors.  
P. Yaish, A. Gazit, C. Gilon and A. Levitzki.  
Science, 242, 933-935 (1988).

149. Transmembrane signalling in *Saccharomyces cerevisiae*.  
D. Engelberg, R. Perlman and A. Levitzki.  
Trends in Biochem. Sci (TIBS), 9, 298-301 (1988).
150. Use of electrofocusing for the analysis and purification of turkey erythrocytes 1 -  
adrenoceptors.  
I. Marbach, A. Levitzki.  
FEBS Lett 233, 186-190, (1990).
151. Inhibition of insulin dependent lipogenesis and antilipolysis by protein tyrosine kinase  
inhibitors.  
Y. Shechter, P. Yaish, M. Chorev, C. Gilon, S. Braun and A. Levitzki.  
EMBO J., 8 (6) 1671-1676 (1989).
152. Tyrphostins inhibit EGF receptor tyrosine kinase activity in living cells and EGF-stimulated  
cell proliferation.  
R.M. Lyall, A. Zilberstein, A. Gazit, C. Gilon, A. Levitzki, and J. Schlessinger.  
J. Biol. Chem., 264, 14503-14509 (1989).
153. Tyrphostins I: Synthesis and biological activity of protein tyrosine kinase inhibitors.  
A. Gazit, P. Yaish, C. Gilon, and A. Levitzki.  
J. Med. Chem., 32, 2344-2352 (1989)
154. EGF induces tyrosine phosphorylation of phospholipase CII: A potential mechanism for  
EGF-receptor signalling.  
B. Margolis, S-G., Phee, S. Felder, R. Lyall, A. Levitzki, A. Ullrich, A. Zilberstein, and J.  
Schlessinger.  
Cell, 57, 1101-1107 (1989).
155. Mammalian glyceraldehyde-3-phosphate dehydrogenase and its use to elucidate molecular  
mechanisms of cooperativity.  
Y.I. Henis and A. Levitzki.  
In "Allosteric Enzymes" (G. Herve, ed.) CRC Press, Inc., pp. 153-188 (1989).
156. Rapid intracellular alkalinization of *Saccharomyces cerevisiae* MAT $\alpha$  Cells in response to  $\alpha$ -  
factor requires the CDC25 gene product.  
R. Perlman, Y. Eylam, E. Padan, G. Simchen and A. Levitzki.  
Cell. Sig., 1, (6) 577-586 (1989)
157. Tyrphostins inhibit the Epidermal growth factor receptor mediated breakdown of  
phosphoinositides.  
I. Posner, A. Gazit, C. Gilon and A. Levitzki.  
FEBS Lett., 257, 287-291 (1989).
158. Tyrphostins: A new class of tyrosine kinase inhibitors that selectively blocks EGF -  
dependent cell proliferation.  
C. Gilon, A. Gazit, P. Yaish, A. Levitzki.  
Pep., 1-2 (1989)
159. *In vitro* reconstitution of CDC25 regulated *S. cerevisiae* adenylyl cyclase and its kinetic  
properties.  
D. Engelberg, G. Simchen and A. Levitzki.  
EMBO J. 9(3) 641-651 (1990).
160. Dual control of adenylate cyclase in "G proteins as mediators of the cellular signalling  
process".  
Editors: M.D. Houslay and G. Milligan.  
John Wiley and Sons, 1-14 (1990).

161.  $\beta$  subunit co-purifies with GPPNHP activated adenylate cyclase.  
I. Marbach, A. Bar Sinai, M. Minich, and A. Levitzki.  
J. Biol. Chem., 265, 9999-10004 (1990)
162. Analytical determination of receptor-ligand dissociation constants of two populations of receptors from displacement curves.  
H. Almagor, and A. Levitzki  
Proc. Nat. Acad. Sci. 87, 6482-6486 (1990)
163. Adenylyl cyclase activity of fission yeast *Schizosaccharomyces.pombe* is not regulated by guaryl nucleotides.  
D. Engelberg, E. Paradosu, G. Simchen and Levitzki.  
FEBS Lett 261, 413, (1990).
164. Tyrphostins-potential antiproliferative agents and novel molecular tools.  
A. Levitzki.  
Biochem. Pharmacol, 40, 913-918 (1990)
165. GTP-GDP Exchange Proteins.  
A. Levitzki.  
Science 248, 794 (1990).
166. Tyrosine phosphorylation is an essential event in the stimulation of B lymphocytes by *Staphylococcus Aureus* Cowen I.  
C. Roifman, G.B. Mills, K. Chin, A. Gazit, C. Gilon and A. Levitzki.  
J. Immunol, 146, 2965-2971 (1991).
167. Tyrphostins II: Heterocyclic and  $\alpha$ -substituted Benzonemaloronitrile Tyrphostins as Potent Inhibitors of EGF Receptor and ErbB2/neu Tyrosine kinases.  
A. Gazit, N. Osherov, I. Posner, R. Yaish, E. Paradosu, C. Gilon and A. Levitzki.  
J. Med. Chem., 34, 1897-1907 (1991).
168. Tyrphostins inhibit PDGF induced DNA synthesis, Tyrosine specific protein kinase activity and c-fos mRNA expression in vascular smooth muscle cells.  
G. Bilder, J.A. Krawiec, A. Gazit, C. Gilon, K. McVety, R. Lyall, A. Zilberstein, A. Levitzki, M. Perrone and A.B. Schreiber.  
American J. Physiol., 260, c721-c730 (1991).
169. Activation of phospholipase C in human B cells is dependent on tyrosine phosphorylation.  
S. Padeh, A. Levitzki, A. Gazit, G.B. Mills and C.M. Roifman.  
J. Clin. Investigation 87, 1114-1118 (1991).
170. Tyrphostins as potential antiproliferative drugs and useful molecular tools.  
A. Levitzki and C. Gilon.  
Trends in Pharmacol. Sci., 12, 171-174.
171. The inhibition of EGF-dependent proliferation of keratinocytes by tyrosine kinase blockers.  
A. Dvir, Y. Milner, O. Chomsky, C. Gilon, A. Gazit and A. Levitzki.  
J. Cell Biol., 113, 857-865 (1991).
172. Erbstatin and tyrphostins block protein serine kinase activation and meiotic maturation of sea star oocytes  
M. Daya-Makin, S.L. Pelech, A. Levitzki and A. Hudson  
Biochim. Biophys. Acta, 1093, 87-94 (1991).
173. The antiproliferative effects of tyrosine kinase inhibitor tyrphostin on a human squamous cell carcinoma *in vitro* and in nude mice. Yoneda, T., Lyall, R., Alsine M.M., Pearsons, P.E., Spada, A.P., Levitzki, A., Zilberstein, A. and Mundy, G.R., Cancer Res., 51, 4430-4435, (1991).

174. Tyrosine kinase blockers: New platelet activation inhibitors.  
F. Rendu, A. Eldor, F. Gerlac, S. Levy-Toledano and A. Levitzki.  
*Blood Coagulation and Fibrinolysis*, 1, 713-716 (1991).
175. Inhibition of protein tyrosine kinases by tyrphostins.  
A. Levitzki, A. Gazit, N. Osherov, I. Posner and C. Gilon.  
*Meth. in Enzymol*, 201, 347-361, (1991).
176. Tyrphostins as molecular tools and potential antiproliferative drugs.  
C. Gilon, A. Levitzki.  
*Trends in Pharmacol. Sci. (TIPS)*, 12, 171-174 (1991).
177. Cellular Signaling.  
A. Levitzki.  
*Enc. of Human Biology*, 2, 321-331 (1991).
178. Kinetic analysis of the inhibition of the EGF receptor tyrosine by Lavenohistin-A and its analogue.  
C.Y.J. Hsu, P.E. Persons, A.P. Spada, R.A. Bendar, A. Levitzki and Z. Zillerstein. *J. Biol. Chem.*, 266, 21105-21112 (1991).
179. Inhibition of platelet derived growth factor (PDGF) induced mitogenic activity by PDGF receptor tyrosine kinase tyrphostin inhibitors.  
M.C. Bryckaert, A. Eldor, A. Gazit, N. Osherov, C. Gilon, M. Fontenay, A. Levitzki and G. Tobelem.  
*Exp. Cell Res.*, 199, 255-261 (1992).
180. Regulation of Hormone and transmitter sensitive adenylyl cyclase.  
A. Bar-Sinai, I. Marbach and A. Levitzki.  
*Topics in Pharmaceutical Sciences*, 557-563 (1992).
181. Selective Interactions of transforming and normal *abl* proteins with ATP, tyrosine copolymer substrates and tyrphostins.  
M. Anafi, A. Gazit, C. Gilon, Y. Ben-Neriah and A. Levitzki  
*J. Biol. Chem.*, 267, 4518-4523 (1992).
182. The effect of tyrosine specific protein phosphorylation on the assembly of adherens-type junctions.  
T. Volberg, Y. Zick, R. Dior, I. Sabanay, C. Gilon, A. Levitzki and B. Geiger. *EMBO J.*, 11, 1733-1742 (1992).
183. Anti-CDC25 antibodies inhibit guanyl nucleotide dependent adenylyl cyclase of *S. cerevisiae* and cross react with putative CDC25 mammalian homologs.  
E. Gross, I. Marbach, D. Engelberg, M. Segal, and A. Levitzki  
*Mol. Cell. Biol.*, 12, 2653-2661 (1992).
184. Inhibition of platelet activation by tyrosine kinase inhibitors.  
F. Rendu, A. Eldor, F. Gerlac, C. Bachelot, A. Gazit, C. Gilon, S. Levy-Toledano and A. Levitzki.  
*Biochem. Pharmacol.*, in press.
185. The regulation of adenylyl cyclase by receptor operated G-proteins  
A. Levitzki and A. Bar Sinai  
*The International Encyclopedia of Pharmacology and Therapeutics*, in press, (Pergamon Press).
186. Tyrphostins - a novel concept for antiproliferative drugs.  
A. Levitzki and C. Gilon in "Frontiers in Pharmacology and Therapeutics", eds. Blackwell, in press.

187. GPPNHP activated adenylate cyclase from turkey erythrocytes possesses the  $\beta\gamma$ -subunits.  
A. Bar-Sinai, I. Marbach and A. Levitzki  
Eur. J. Biochem., in press.
188. Kinetic Model for the Epidermal Growth Factor (EGF) Receptor tyrosine kinase and a possible mechanism of its activation by EGF.  
I. Posner, M. Ergel and A. Levitzki, J. Biol. Chem., in press.
189. Tyrphostins: tyrosine kinase blockers as novel antiproliferative agents and dissectors of signal transduction.  
A. Levitzki, FASEB Journal, in press.
190. Interaction between the *S. cerevisiae* CDC25 gene product and mammalian ras.  
Segal, M., Engelberg, D. Marbach, I. Simchen, G. and Levitzki, A.  
J. Biol. Chem., in press.
191. Tyrphostins inhibit FSH mediated functions in cultured rat ovarian granulosa cells  
S. Gornberg-Malool, R. Ziv, I. Posner, A. Levitzki and J. Orly.  
in press.
192. Role of pp180 as mediator of insulin action.  
Y. Zik, D. Heffetz, A. Gazit and A. Levitzki.  
Submitted.
193. A. *Candida albicans* homologs of CDC25 is functional in *S. cerevisiae*.  
D. Goldberg, G. Simchen, and A. Levitzki.  
Submitted.
194. Cdc25 mediates Cross-Talk between the Growth Signalling Pathway and the Mating Pathway of *S. cerevisiae*  
R. Perlman, G. Simchen and A. Levitzki.  
Submitted.
195. Kinetics of Inhibition of the tyrosine kinase activity of the epidermal growth factor receptor by tyrphostins.  
I. Posner, M. Engel, A. Gazit and A. Levitzki.  
Submitted.
196. Selective inhibition of the EGF and Neu receptor  
N. Osherov, A. Gazit, C. Gilon and A. Levitzki  
Submitted.

## Worldwide Patents

1. Benzylidene and cinnamylidene-malonitrite derivatives for the inhibition of proliferative processes in mammalian cells. 1988.  
A. Levitzki, A. Gazit, C. Gilon and M. Chorev.
2. Low molecular weight styryl compounds which inhibit EGF receptor PTK activity. 1990.  
A. Levitzki, A. Gazit and C. Gilon.
3. Heterocyclic ether diyl compounds which inhibit EGF receptor PTK activity. 1990.  
A. Levitzki, A. Gazit and C. Gilon.

4. Heteroarylethenediyl monocyclic and bicyclic heteroaryl compounds.1990.  
A. Levitzki, A. Gazit and C. Gilon.